EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy

Debora Pires-Ferreira, Darcy Reil, Qiushi Tang, Meghan Blackwood, Thomas Gallagher iD, Allison M Keeler iD, Jessica A Chichester iD, Kristin K Vyhnal, Jane A Lindborg, Janet Benson, Dongtao Fu, Terence R Flotte iD und 1 weitere

Genes · 2024

DOI: 10.3390/genes15091188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Debora Pires-Ferreira und 12 weiteren Autor:innen. Beteiligte Einrichtung: Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, Dependovirus, Genetic Vectors, Genetic Therapy. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, ORFDO NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: α-1 antitrypsin (AAT) deficiency is an inherited, genetic condition characterized by reduced serum levels of AAT and increased risk of developing emphysema and liver disease. AAT is normally synthesized primarily in the liver, but muscle-targeting with a recombinant adeno-associated virus (rAAV) vector for α-1 antitrypsin (AAT) gene therapy has been used to minimize liver exposure to the virus and hepatotoxicity. Clinical trials of direct intramuscular (IM) administration of rAAV1-hAAT have demonstrated its overall safety and transgene expression for 5 years. However, the failure to reach the therapeutic target level after 100 large-volume (1.5 mL) IM injections of maximally concentrated vector led us to pursue a muscle-targeting approach using isolated limb perfusion. This targets the rAAV to a greater muscle mass and allows for a higher total volume (and thereby a higher dose) than is tolerable by multiple direct IM injections. Limb perfusion has been shown to be feasible in non-human primates using the rAAV1 serotype and a ubiquitous promoter expressing an epitope-tagged AAT matched to the host species.

Methods

In this study, we performed a biodistribution and preclinical safety study in non-human primates with a clinical candidate rAAV1-human AAT (hAAT) vector at doses ranging from 3.0 × 1012 to 1.3 × 1013 vg/kg, bracketing those used in our clinical trials.

Results

We found that limb perfusion delivery of rAAV1-hAAT was safe and showed a biodistribution pattern similar to previous studies. However, serum levels of AAT obtained with high-dose limb perfusion still reached only ~50% of the target serum levels.

Conclusions

Our results suggest that clinically effective AAT gene therapy may ultimately require delivery at doses between 3.5 × 1013–1 × 1014 vg/kg, which is within the dose range used for approved rAAV gene therapies. Muscle-targeting strategies could be incorporated when delivering systemic administration of high-dose rAAV gene therapies to increase transduction of muscle tissues and reduce the burden on the liver, especially in diseases that can present with hepatotoxicity such as AAT deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-AntitrypsinDependovirusGenetic VectorsGenetic Therapyalpha 1-Antitrypsin DeficiencyAnimalsHumansMaleMuscle, Skeletal

Stichwörter der Autor:innen

AATD gene therapyalpha-1 anti-trypsinbiodistributionpre-clinical studyrAAV gene therapyrAAV safety

Substanzen

alpha 1-Antitrypsin

Autor:innen und Institutionen

  • Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • NeuroNexus Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
  • Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.
  • Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.

ORCID-Profile: Thomas Gallagher, Allison M Keeler, Jessica A Chichester, Terence R Flotte

Förderung

  • NHLBI NIH HHS
  • ORFDO NIH HHS
  • NIH HHS
  • National Heart, Lung, and Blood Institute (NHLBI) of the NIH
  • NHLBI Catalyze Program
  • NHLBI

Zitieren

APA

Pires-Ferreira, D., Reil, D., Tang, Q., Blackwood, M., Gallagher, T., Keeler, A. M., Chichester, J. A., Vyhnal, K. K., Lindborg, J. A., Benson, J., Fu, D., Flotte, T. R., & Gruntman, A. M. (2024). Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy. Genes. https://doi.org/10.3390/genes15091188

Vancouver

Pires-Ferreira D, Reil D, Tang Q, Blackwood M, Gallagher T, Keeler AM, et al. Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy. Genes. 2024. doi:10.3390/genes15091188

BibTeX
@article{PiresFerreira2024,
  author = {Pires-Ferreira, Debora and Reil, Darcy and Tang, Qiushi and Blackwood, Meghan and Gallagher, Thomas and Keeler, Allison M and Chichester, Jessica A and Vyhnal, Kristin K and Lindborg, Jane A and Benson, Janet and Fu, Dongtao and Flotte, Terence R and Gruntman, Alisha M},
  title = {Limb Perfusion Delivery of a rAAV1 Alpha-1 Antitrypsin Vector in Non-Human Primates Is Safe but Insufficient for Therapy},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15091188}
}
Kostenlos starten →